BANU K ARUN to Germ-Line Mutation
This is a "connection" page, showing publications BANU K ARUN has written about Germ-Line Mutation.
Connection Strength
4.121
-
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. Eur J Cancer. 2021 09; 154:35-45.
Score: 0.515
-
Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. Breast J. 2020 08; 26(8):1572-1582.
Score: 0.477
-
Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer. 2018 02 06; 18(1):152.
Score: 0.406
-
Genotype in BRCA-associated breast cancers. Breast J. 2013 Jan-Feb; 19(1):87-91.
Score: 0.284
-
Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012 Feb 15; 118(4):908-13.
Score: 0.258
-
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. Br J Cancer. 2024 Nov; 131(9):1400-1414.
Score: 0.160
-
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024 Jul 20; 42(21):2599-2615.
Score: 0.157
-
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline Clinical Insights. JCO Oncol Pract. 2024 Oct; 20(10):1308-1313.
Score: 0.157
-
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Cancer. 2024 May 01; 130(9):1600-1608.
Score: 0.152
-
Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing. Ann Surg Oncol. 2023 Mar; 30(3):1663-1668.
Score: 0.140
-
Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):437-444.
Score: 0.131
-
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021 03; 146:30-47.
Score: 0.125
-
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019 12; 76(6):831-842.
Score: 0.114
-
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
Score: 0.113
-
Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):101-109.
Score: 0.102
-
Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget. 2016 Dec 06; 7(49):80465-80481.
Score: 0.094
-
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res. 2016 11 11; 18(1):112.
Score: 0.093
-
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol. 2016 05; 27(5):795-800.
Score: 0.088
-
High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 01; 121(19):3422-7.
Score: 0.086
-
Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005 Aug 01; 11(15):5401-9.
Score: 0.043
-
Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data. J Clin Oncol. 2024 Jun 20; 42(18):2186-2195.
Score: 0.039
-
Hematologic malignancies in Li-Fraumeni syndrome: A case report. Am J Med Genet A. 2024 07; 194(7):e63573.
Score: 0.039
-
LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations. JCO Clin Cancer Inform. 2024 Feb; 8:e2300167.
Score: 0.038
-
NCCN Guidelines? Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. J Natl Compr Canc Netw. 2023 10; 21(10):1000-1010.
Score: 0.038
-
ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk. Clin Cancer Res. 2023 08 15; 29(16):3037-3050.
Score: 0.037
-
Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clin Cancer Res. 2022 09 01; 28(17):3669-3676.
Score: 0.035
-
Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):426-436.
Score: 0.033
-
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 10; 21(10):1269-1282.
Score: 0.030
-
The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2019 11 15; 105(4):698-712.
Score: 0.028
-
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol. 2018 11 01; 36(31):3134-3143.
Score: 0.027
-
Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. Oncologist. 2017 06; 22(6):655-666.
Score: 0.024
-
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 01; 23(15):4066-4076.
Score: 0.024
-
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol. 2015 Nov 01; 33(31):3660-7.
Score: 0.021
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24; 376(9737):235-44.
Score: 0.015